Clinical Trials Logo

Body Weight clinical trials

View clinical trials related to Body Weight.

Filter by:

NCT ID: NCT05203900 Completed - Clinical trials for Low Birth Weight Infants

The Influence by Dietary Human Milk Oligosaccharide in Low Birth Weight Infants

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

This study aims to investigate the concentration of various growth factors and cytokines in blood, and to examine the gut microbiota of low birth weight infants fed with formulas with or without Human Milk Oligosaccharide (HMO) supplement. Eligible low birth weight infants are allocated to two groups, Investigational formula (with HMO) or Control formula (without HMO). The subjects are taking the assigned formula when they need to be supplemented with formula. After the informed consent was obtained and eligibility was confirmed, the intervention period begins, and ends at the one-month-old medical check-up with the assessment of the various blood growth factors and cytokines, and the gut microbiota.

NCT ID: NCT05200520 Completed - Obesity Clinical Trials

Improving Appetite Regulation in Patients With Obesity

Start date: March 5, 2022
Phase: N/A
Study type: Interventional

Over 70% of U.S. adults have overweight or obesity. Currently, the most efficacious behavioral intervention for obesity is standard behavioral treatment (SBT), often composed of group sessions, calorie goals, and physical activity goals. With this approach, participants often lose 8-10% of the person's baseline weight, and also decrease risk for cardiovascular disease. Long-term weight loss, however, is limited; many participants return to baseline weight within five years following treatment. One reason SBT may not create long-term weight loss may be due to treatment components that teach participants to rely on external methods for changing eating decisions (e.g., counting calories, restricting certain foods), rather than internal cues of hunger and satiety. Because individuals with obesity report significant challenges with adhering to these cues, augmenting behavioral interventions with appetite self-regulation training may be a solution. Thus, the investigator propose to examine the feasibility and acceptability of a 6-month remotely-delivered appetite regulation + lifestyle modification intervention to treat obesity.

NCT ID: NCT05181176 Recruiting - Body Weight Clinical Trials

Effect of Coffee and Tea Consumption on Adolescent Weight Control

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Introduction: The influence of tea or coffee supplementation on body weight in adolescents has never been tested. The aim of the present study was to investigate the effect of tea and coffee consumption on body weight and body fat in an obese adolescent population. Methods: Randomized clinical trial, parallel group study comparing 3 weight loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea). Sociodemographic data and medical history details were retrieved from medical files. The body mass index Z (BMI Z) score and fat percentage as measured by bioelectrical impedance were compared between groups at 3 and 6 months.

NCT ID: NCT05177705 Recruiting - Pediatric Obesity Clinical Trials

The Intersection Between Loss of Control Eating and Obesity: The Role of Restriction and Food Reinforcement

Start date: November 11, 2021
Phase: Early Phase 1
Study type: Interventional

This study aims to determine the relationships among loss of control eating, restriction, relative reinforcing value of high energy-dense food, and obesity risk. In order to achieve this aim, the investigators will follow children over the course of a year, obtaining behavioral and observational measurements, in addition to a two-week restricted access and two week non-restricted access period.

NCT ID: NCT05170919 Enrolling by invitation - Clinical trials for Anorexia Nervosa With Significantly Low Body Weight

Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage Cancer

Start date: January 20, 2022
Phase: Phase 2
Study type: Interventional

To determine whether olanzapine or mirtazapine is more effective in preventing weight loss and appetite loss in cancer patients.

NCT ID: NCT05163587 Completed - Hyperlipidemias Clinical Trials

Composite Flour and Its Antdiabetic Potential

Start date: March 26, 2021
Phase: N/A
Study type: Interventional

A low glycemic multigrain flour for chapattis will be made from grains and cereals that are easily available in Pakistan. The nutritional profile and composition of test flour will be checked through proximate analysis method determined by AOAC. GI of test flour will be determined by comparing it with a reference food. The participants will be fed reference food i.e., 50gm glucose dissolved in 250ml water and test food serving having 50gm of available carbohydrates separately after an overnight fast. Finger prick method will be used to determine blood glucose levels at 0,15, 30, 45, 90 minutes. Trapezoidal rule will be used to determine iAUC and GI and GL will be determined by using standard formulas. Efficacy of test flour will be checked by human clinical trial. Control group will be fed chapatis made from test flour for 90 days. Anthropometry, body composition and biochemical measures including HbA1c, blood glucose (fasting and random) and lipid profile will be analyzed pre- and post-intervention and differences in their readings will be compared.

NCT ID: NCT05162001 Enrolling by invitation - Obesity; Drug Clinical Trials

Body Weight Response With Disulfiram in Humans

Start date: November 21, 2021
Phase: Early Phase 1
Study type: Interventional

Overweight and obesity due to food that exceeds the requirements is an increasingly common global problem. Lifestyle intervention and anorectic drugs result in minimal weight loss, which tends to be easily regained. In addition, drugs tend to have too many side effects and have had to be withdrawn from management schemes and even from the market. Disulfiram (Antabuse®️) is approved by the Food and Drug Administration against chronic alcohol addiction. In a mouse study, disulfiram prevented body weight gain and negated the adverse impact of an obesogenic diet on insulin; used properly it is a safe drug. Carrying out a testing-concept study with disulfiram will allow the establishment of guidelines on clinical studies focused on its use as an adjunct in the reduction and control of body weight.

NCT ID: NCT05145504 Completed - Clinical trials for IL-6 Concentration in the Synovial Fluid of Obese Patients is 100% Higher Than the IL-6 Concentration of the Synovial Fluid in Normal Weight Patients

Evaluation of IL-6 in Synovial Fluid in Obese and Normal Weight Patients Suffering From Gonarthrosis During PTA

IL6PG
Start date: November 18, 2021
Phase:
Study type: Observational

Evaluate the concentration of IL-6 in the synovial fluid of obese patients suffering from gonarthrosis during knee arthroplasty surgery

NCT ID: NCT05144490 Completed - Exercise Clinical Trials

The Effect of Brief Bodyweight Exercise on Acute Glycemic Control in Healthy Inactive Adults

Start date: December 6, 2021
Phase: N/A
Study type: Interventional

This study will investigate whether an 11-minute bodyweight exercise session can improve short-term glycemic control. Glycemic control refers to the process of how the body regulates blood sugar. The process can be measured in different ways. This study will use a small device called a continuous glucose monitor to measure changes in glucose levels over a 24-hour period. Participants will complete two trials and the investigators will compare glycemic control after the exercise session and a control period that does not involve exercise. Food intake will be controlled such that each participant will consume the same diet in both conditions. This study will help determine whether a single session of bodyweight exercise affects glycemic control.

NCT ID: NCT05141526 Recruiting - Weight Loss Clinical Trials

Satiating Diet, Appetite Control and Body Weight Loss in Individuals With Obesity

Start date: January 15, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate (1) the effect of a non-restrictive satiating intervention on appetite control, body weight loss and maintenance; and (2) determine whether switching to a non-restrictive satiating intervention following a conventional restrictive intervention can prevent increases in appetite and attenuate body weight regain usually observed after weight loss in men and women living with obesity. This is an 18-month, randomized, controlled, parallel weight loss [Phase 1 (P1): 6 months] and maintenance trial [Phase 2 (P2): 12 months] with three groups (n=234 men and women): (1) non-restrictive, satiating intervention (P1) followed by a continuation of this intervention (P2); (2) conventional restrictive intervention (-500 kcal/d) (P1) followed by a non-restrictive satiating intervention (P2); (3) control group that follows minimal healthy guidelines (P1) followed by recommended weight maintenance strategies (P2). All groups will be controlled for physical activity and sleep patterns. The non-restrictive satiating intervention will include guidelines and recipes to prepare highly satiating meals that will be low in energy density and glycemic index and high in protein, polyunsaturated fats, vitamins and minerals (e.g. calcium), and certain constituents of spices (e.g. capsaicin). Measurements at baseline (week 0), after P1 and P2 will include the following primary outcomes: appetite control, weight loss and maintenance; and secondary outcomes: body composition, physiological, psycho and neurobehavioural and health-related variables. Follow-ups will be done by a dietitian every 2 weeks during P1 and once a month during P2.